167 related articles for article (PubMed ID: 37541594)
1. Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy.
Huang J; Yao Z; Li B; Ping Y
J Control Release; 2023 Sep; 361():270-279. PubMed ID: 37541594
[TBL] [Abstract][Full Text] [Related]
2. Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation.
Bi T; Liang P; Zhou Y; Wang H; Huang R; Sun Q; Shen H; Yang S; Ren W; Liu Z
J Med Chem; 2023 Nov; 66(21):14843-14852. PubMed ID: 37871321
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
Yang C; Yang Y; Li Y; Ni Q; Li J
J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
[TBL] [Abstract][Full Text] [Related]
4. Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation.
Chang M; Gao F; Pontigon D; Gnawali G; Xu H; Wang W
J Am Chem Soc; 2023 Jun; 145(25):14155-14163. PubMed ID: 37327395
[TBL] [Abstract][Full Text] [Related]
5. Senolysis Enabled by Senescent Cell-Sensitive Bioorthogonal Tetrazine Ligation.
Chang M; Dong Y; Xu H; Cruickshank-Taylor AB; Kozora JS; Behpour B; Wang W
Angew Chem Int Ed Engl; 2024 Feb; 63(9):e202315425. PubMed ID: 38233359
[TBL] [Abstract][Full Text] [Related]
6. Stimuli-activatable PROTACs for precise protein degradation and cancer therapy.
Gao J; Yang L; Lei S; Zhou F; Nie H; Peng B; Xu T; Chen X; Yang X; Sheng C; Rao Y; Pu K; Jin J; Xu Z; Yu H
Sci Bull (Beijing); 2023 May; 68(10):1069-1085. PubMed ID: 37169612
[TBL] [Abstract][Full Text] [Related]
7. Bioorthogonal micellar nanoreactors for prodrug cancer therapy using an inverse-electron-demand Diels-Alder reaction.
Suehiro F; Fujii S; Nishimura T
Chem Commun (Camb); 2022 Jun; 58(50):7026-7029. PubMed ID: 35642953
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy.
Zou ZF; Yang L; Nie HJ; Gao J; Lei SM; Lai Y; Zhang F; Wagner E; Yu HJ; Chen XH; Xu ZA
Acta Pharmacol Sin; 2024 Apr; ():. PubMed ID: 38609561
[TBL] [Abstract][Full Text] [Related]
9. Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy.
Gao J; Hou B; Zhu Q; Yang L; Jiang X; Zou Z; Li X; Xu T; Zheng M; Chen YH; Xu Z; Xu H; Yu H
Nat Commun; 2022 Jul; 13(1):4318. PubMed ID: 35882867
[TBL] [Abstract][Full Text] [Related]
10. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
11. Intracellular fluorogenic supramolecular assemblies for self-reporting bioorthogonal prodrug activation.
Zhao Y; Yao Q; Chen J; Zhang R; Song J; Gao Y
Biomater Sci; 2022 Sep; 10(19):5662-5668. PubMed ID: 35996984
[TBL] [Abstract][Full Text] [Related]
12. Radiation responsive PROTAC nanoparticles for tumor-specific proteolysis enhanced radiotherapy.
Xu M; Yun Y; Li C; Ruan Y; Muraoka O; Xie W; Sun X
J Mater Chem B; 2024 Mar; 12(13):3240-3248. PubMed ID: 38437473
[TBL] [Abstract][Full Text] [Related]
13. BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes.
Ma L; Wang J; Zhang Y; Fang F; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Sang X; Zhang K; Lu L; Wan X; Chen Y; Yu J; Zhuo R; Wu S; Lu J; Pan J; Hu S
Cancer Biol Ther; 2022 Dec; 23(1):1-15. PubMed ID: 36170346
[TBL] [Abstract][Full Text] [Related]
14. Activation and Delivery of Tetrazine-Responsive Bioorthogonal Prodrugs.
Wang Y; Zhang C; Wu H; Feng P
Molecules; 2020 Nov; 25(23):. PubMed ID: 33266075
[TBL] [Abstract][Full Text] [Related]
15. Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy.
He Q; Zhou L; Yu D; Zhu R; Chen Y; Song M; Liu X; Liao Y; Ding T; Fan W; Yu W
J Med Chem; 2023 Aug; 66(15):10458-10472. PubMed ID: 37279091
[TBL] [Abstract][Full Text] [Related]
16. [Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy].
Wu X; Zhao J; Gao Y; Yao Q; Xie J
Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3628-3643. PubMed ID: 37805843
[TBL] [Abstract][Full Text] [Related]
17. The Emerging Role of Tetrazines in Drug-Activation Chemistries.
Neumann K; Gambardella A; Bradley M
Chembiochem; 2019 Apr; 20(7):872-876. PubMed ID: 30394615
[TBL] [Abstract][Full Text] [Related]
18. Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors.
Fan H; Zhou Z; Yu D; Sun J; Wang L; Jia Y; Tian J; Mi W; Sun H
Bioorg Chem; 2023 Nov; 140():106793. PubMed ID: 37683536
[TBL] [Abstract][Full Text] [Related]
19. Tetrazine-Triggered Bioorthogonal Cleavage of trans-Cyclooctene-Caged Phenols Using a Minimal Self-Immolative Linker Strategy.
Keppel P; Sohr B; Kuba W; Goldeck M; Skrinjar P; Carlson JCT; Mikula H
Chembiochem; 2022 Oct; 23(20):e202200363. PubMed ID: 35921044
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.
He S; Fang Y; Wu M; Zhang P; Gao F; Hu H; Sheng C; Dong G
J Med Chem; 2023 Dec; 66(24):16828-16842. PubMed ID: 38055861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
